65,437 trials
Dry Eye Disease (DED)
Primary: Number of Participants With Ocular and Non-ocular Adverse Events — 69; 14; 1; 9 Participants
Neonatal Death · Perinatal Death · Depression
Primary: Acceptability — 4.0 units on a scale
Type 2 Diabetes
Primary: Body Mass Index (BMI) — 32.95 kg/m^2
Beta-Thalassemia
Primary: Percentage of Participants Who Have Achieved Transfusion Independence (TI) — 88.9 Percentage of participants
Esophageal Squamous Cell Carcinoma (ESCC)
Primary: Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set — 8.6; 6.3 Months — p=0.0001
Major Depression
Primary: Change in Targeted Ventromedial Prefrontal Cortex-Ventral Striatal (vmPFC-VS) Functional Connectivity (FC) — 0.02; -0.13; 0.02; 0.09 Z-score
Hiv
Primary: Wilson Self-reported Medication Adherence Scale — 77.48; 71.59 score on a scale
Hypertension
Primary: Treatment Intensification — 21; 23; 19 Participants
Cognition Disorders
Primary: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score — -1.43; -1.13 score on a scale — p=0.260
Chronic Inflammation
Primary: Number of Differentially Expressed Genes — 8.3 Differentially expressed genes
Geographic Atrophy · Macular Degeneration
Primary: The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12 — 0.336; 0.392…
Acne
Primary: Percent Change From Baseline in Total Lesions at Week 12 — -17.1; -45.6; -13.0; 7.6 Percent change in lesions
Sleep Apnea, Obstructive · Hypotonia · Child, Only
Primary: Ability to Tolerate Measured by Percent of Participants With Protocol Goal — 50 percent of participants
Angioedema
Primary: Number of Investigator-Confirmed Angioedema Attacks During the Treatment Period of Day 0 Through Day 182 — 1.63; 2.17 attacks/month — p==0.899
Hospitalization · Infection
Primary: Hospital Transfers Due to Infection — 1243; 1780 Transfers — p=<0.001